Warrior Met Coal LLC(HCC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

HCC Warrior Met Coal LLC

Pre-Mkt 09-22 09:19:31 EDT

88.47

+0.54

+0.61%

盘前85.08

-3.39-3.83%

08:40 EDT

High89.48	Low88.16	Vol503.15K
Open89.26	D1 Closing87.93	Amplitude1.51%
Mkt Cap4.65B	Tradable Cap4.58B	Total Shares52.57M
T/O44.61M	T/O Rate0.97%	Tradable Shares51.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"HCC","market":"US","secType":"STK","nameCN":"Warrior Met Coal LLC","latestPrice":88.47,"timestamp":1790020800000,"preClose":87.93,"halted":0,"volume":503152,"hourTrading":{"tag":"盘前","latestPrice":85.08,"preClose":88.47,"latestTime":"08:40 EDT","volume":3,"amount":259.008,"timestamp":1790080853842,"change":-3.39,"changeRate":-0.038318,"amplitude":0.042591},"delay":0,"changeRate":0.006141248720573092,"floatShares":51775204,"shares":52570156,"eps":4.16,"marketStatus":"Pre-Mkt","change":0.54,"latestTime":"09-22 09:19:31 EDT","open":89.26,"high":89.48,"low":88.155,"amount":44609028.6408,"amplitude":0.015069,"askPrice":96.09,"askSize":410,"bidPrice":85.08,"bidSize":100,"shortable":3,"etf":0,"ttmEps":4.16,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790083800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":720248400000,"exchange":"NYSE","adjPreClose":88.47,"dividendRate":0.003617,"preHourTrading":{"tag":"盘前","latestPrice":85.08,"preClose":88.47,"latestTime":"08:40 EDT","volume":3,"amount":259.008,"timestamp":1790080853842,"change":-3.39,"changeRate":-0.038318,"amplitude":0.042591},"postHourTrading":{"tag":"盘后","latestPrice":88.47,"preClose":88.47,"latestTime":"19:30 EDT","volume":50273,"amount":4447636.3444,"timestamp":1790033456622,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4816947162724617,"impliedVol":0.52,"impliedVolPercentile":0.328},"requestUrl":"/m/hq/s/HCC/tweets","defaultTab":"tweets","newsList":[{"id":"2668333039","title":"NYSE Order Imbalance 56938.0 Shares on Sell Side","url":"https://stock-news.laohu8.com/highlight/detail?id=2668333039","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668333039?lang=en_us&edition=fundamental","pubTime":"2026-09-17 03:50","pubTimestamp":1789588208,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nAQN2MJKSS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HCC","COAL","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667001866","title":"RBC Raises Price Target on Warrior Met Coal to $110 From $90, Keeps Sector Perform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2667001866","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667001866?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:23","pubTimestamp":1789557787,"startTime":"0","endTime":"0","summary":"Warrior Met Coal (HCC) has an average rating of overweight and mean price target of $108.71, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4006","COAL","HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667284652","title":"WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2667284652","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667284652?lang=en_us&edition=fundamental","pubTime":"2026-09-14 17:59","pubTimestamp":1789379940,"startTime":"0","endTime":"0","summary":"NANJING, China, Sept.  14, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that updated Phase II data for opamtistomig ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/14/3360871/0/en/wclc-2026-leads-biolabs-opamtistomig-lbl-024-oral-presentation-demonstrates-robust-response-and-pfs-benefits-in-first-line-nsclc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BITY","BITI","OC","CBOY","COAL","BITU","BTCZ","HCC","BTCL","BAGY","BETH","BETE","CBOJ","BTF","BFAP","DFII","BTC","BRRR","BCCC","GBTC","ODD","CBOA","CBXJ","CBXO","BFJL","EZBC","BTCI","BITO","ALK","CBXY","BPI","DEFI","BTCO","BTCW","MAXI","HODL","BTCC","YBTC","CBTA","L","XTN","CBTO","CBXA","SBIT","CBOO","BTRN","BITX","XHB","MNRS","BITB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587942","title":"Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587942","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587942?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel, Sept","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358498/0/en/can-fite-publication-reports-improvement-in-decompensated-cirrhosis-with-namodenoson-and-successful-bridging-to-liver-transplantation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","COAL","HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320770","title":"Press Release: Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320770","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320770?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:20","pubTimestamp":1788870000,"startTime":"0","endTime":"0","summary":"RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","COAL","EMA","CANF","BK4139","PRGS","BK4097","LU2065732104.USD","BK4006","HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664812376","title":"Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2664812376","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664812376?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:02","pubTimestamp":1788354120,"startTime":"0","endTime":"0","summary":"RAMAT GAN, Israel, Sept.  02, 2026 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355212/0/en/can-fite-announces-exercise-of-warrants-for-approximately-4-0-million-in-gross-proceeds.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAL","BK4006","HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664068815","title":"Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2664068815","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664068815?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:00","pubTimestamp":1788346800,"startTime":"0","endTime":"0","summary":"Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma Ramat Gan, Israel, Sept.  02, 2026 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3354973/0/en/can-fite-reports-longer-than-anticipated-overall-survival-in-ongoing-pivotal-phase-iii-liver-cancer-study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAL","BK4006","HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664868855","title":"Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664868855","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664868855?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:00","pubTimestamp":1788260400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with ser","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3353946/0/en/parabilis-medicines-to-participate-in-the-morgan-stanley-24th-annual-global-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","XBI","BK4588","PBLS","LU0029874061.USD","COAL","LU0128526141.USD","XLV","LABU","BK4139","BK4585","BK4581","ACP","BK4137","BK4006","HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663021541","title":"Tokio Marine HCC International Acquires UK-Based Direct Commercial","url":"https://stock-news.laohu8.com/highlight/detail?id=2663021541","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663021541?lang=en_us&edition=fundamental","pubTime":"2026-08-31 11:40","pubTimestamp":1788147648,"startTime":"0","endTime":"0","summary":"Tokio Marine (TYO:8766) subsidiary Tokio Marine HCC International acquired UK-based commercial motor managing general agent Direct Commercial, along with the latter's sister company, Direct Commercial","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MARPS","BK4213","COAL","HCC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662058969","title":"Press Release: Akeso 2026 Interim Results: Strong Commercialization Momentum; Io2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's","url":"https://stock-news.laohu8.com/highlight/detail?id=2662058969","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662058969?lang=en_us&edition=fundamental","pubTime":"2026-08-28 10:45","pubTimestamp":1787885100,"startTime":"0","endTime":"0","summary":"HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) (\"Akeso\" or the \"Company\") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051017.SGD","LU2360107325.USD","BK4211","BK4141","CNS","LU1720051108.HKD","LU1794554557.SGD","BK4512","IE00BFMHRM44.USD","LU1548497426.USD","LU2399975544.HKD","LU2357305700.SGD","LU1854104046.USD","LU1861215975.USD","LU1983260115.SGD","LU0348784397.USD","ONX","IE00B543WZ88.USD","LU0348766576.USD","LU0348825331.USD","PFS","LU0417516571.SGD","KURE","LU2476274720.SGD","LU1861220033.SGD","LU0348723411.USD","BK4195","09926","LU2298322129.HKD","LU1861214812.USD","BK1161","HCC","ONG","LU0417516902.SGD","IE00BPRC5H50.USD","COAL","LU0348735423.USD","LU2778985437.USD","BK4006","ON","LU1720050803.USD","LU0561508036.HKD","BK4585","LU0348827113.USD","LU1854103824.USD","IE00B5MMRT66.SGD","LU0634319403.HKD","BK4588","LU2488822045.USD","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195720547","title":"IMMUNEONCO-B Advances Phase II Trial for First-Line Advanced Liver Cancer Therapy With Initial Patient Dosing Completed","url":"https://stock-news.laohu8.com/highlight/detail?id=1195720547","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195720547?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:24","pubTimestamp":1787837055,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) has announced that the Phase II clinical trial evaluating IMM2510 (Peravrafusp alfa) in combination with IMM27M (Tazebsumab) as a first-line treatment for patients with advanced...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDTX","BMED","HCC","01541","COAL","PSYK","IBBJ","BK4006","IBBQ","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662748174","title":"Warrior Met Coal CEO Walter J. Scheller Sells 50,000 Shares for $5.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662748174","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662748174?lang=en_us&edition=fundamental","pubTime":"2026-08-26 23:07","pubTimestamp":1787756865,"startTime":"0","endTime":"0","summary":"Warrior Met Coal CEO Walter J. Scheller sells 50,000 shares for $5.5 millionWarrior Met Coal CEO Walter J. Scheller sold 50,000 common shares on Aug. 24, 2026 at USD 110.The transaction reduced his di","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL5G8dp9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Warrior Met Coal CEO Walter J. Scheller Sells 50,000 Shares for $5.5 Million","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","BK4006","COAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662476232","title":"Warrior Met Coal Inc : Jefferies Raises Target Price to $125 from $110","url":"https://stock-news.laohu8.com/highlight/detail?id=2662476232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662476232?lang=en_us&edition=fundamental","pubTime":"2026-08-26 12:39","pubTimestamp":1787719157,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44M0OU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COAL","HCC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662244736","title":"Press Release: Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2662244736","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662244736?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:00","pubTimestamp":1787655600,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1854104046.USD","BK4139","LU1861215975.USD","BK4555","LU1861214812.USD","LU1854103824.USD","03160","LU1720051108.HKD","COAL","IE00BFMHRM44.USD","LU2298322129.HKD","ON","ACP","BK4232","IE00BZ199S13.USD","LU1983260115.SGD","LU2357305700.SGD","BK4099","LU0348723411.USD","LU1720051017.SGD","BK4604","BK4141","LU0124384867.USD","BK4585","BK4512","LU0724618433.USD","TM","BK4022","LU1861219969.SGD","LU1861220033.SGD","HCC","LU1548497426.USD","R","LU1978683503.SGD","PBLS","BK4588","ONX","ONG","IE00BD6J9T35.USD","BK4006","BK4605","LU2360107325.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662888737","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2662888737","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662888737?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:25","pubTimestamp":1787624700,"startTime":"0","endTime":"0","summary":"NANJING, China, Aug.  24, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s pr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350174/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-phase-ii-clinical-study-for-first-line-treatment-of-esophageal-squamous-cell-carcinoma-advances-to-expansion-stage.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAGY","BTCL","DFII","ORR","CBTY","PD","CBTA","OC","MNRS","BTF","CBOY","BTCW","BPI","CBOJ","BITY","PFS","BFJL","BRRR","BTC","CBOO","YBTC","ODD","COAL","SBIT","EZBC","FBTC","XHB","BETE","CBTJ","BTCC","CBXY","BTRN","BITO","CBOA","GBTC","QBF","BTCZ","BITI","BFAP","BITX","HODL","MAXI","ARKB","CBXO","XBTY","BCCC","BITB","DEFI","HCC","BITU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661410992","title":"Press Release: Antengene Announces 2026 Interim Results: Achieves First","url":"https://stock-news.laohu8.com/highlight/detail?id=2661410992","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661410992?lang=en_us&edition=fundamental","pubTime":"2026-08-24 09:00","pubTimestamp":1787533200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Aug. 23, 2026 /PRNewswire/ -- Antengene Corporation Limited (\"Antengene\", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","HCC","03160","PYZ","COAL","TM","BK4022","CR","ORR","BK4555","XAR","BK4187","LU2065731478.USD","IE0031619046.USD","BK4585","IE00B7SZL793.SGD","BK4588","LU0963586101.USD","BK1574","06996","BK4232","BK4604","BK4099","BK4006","BK1191","IE00B19Z4B17.USD","CRS","BK1583","IE00B66KJ199.SGD","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661429468","title":"Warrior Met Coal Director Stephen D. Williams Sells 4,800 Common Shares Worth $500,304","url":"https://stock-news.laohu8.com/highlight/detail?id=2661429468","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661429468?lang=en_us&edition=fundamental","pubTime":"2026-08-22 01:08","pubTimestamp":1787332125,"startTime":"0","endTime":"0","summary":"Warrior Met Coal director Stephen D. Williams sells 4,800 common shares worth $500,304Warrior Met Coal director Stephen D. Williams sold 4,800 common shares on Aug. 19, 2026 at USD 104.23.Direct holdi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL9TFMR0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Warrior Met Coal Director Stephen D. Williams Sells 4,800 Common Shares Worth $500,304","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","COAL","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660770364","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement","url":"https://stock-news.laohu8.com/highlight/detail?id=2660770364","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660770364?lang=en_us&edition=fundamental","pubTime":"2026-08-20 10:53","pubTimestamp":1787194380,"startTime":"0","endTime":"0","summary":"NANJING, China, Aug.  19, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the full abstract of the Phase II clinic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/20/3348072/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-abstract-published-by-wclc-extended-follow-up-shows-continued-efficacy-improvement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OC","IBIT","COAL","BITI","XBTY","XHB","GBTC","BTC","CBOO","BETE","BFAP","ODD","YBTC","BTCO","BITO","BRRR","BFJL","EZBC","CBXA","BTCW","BTCI","BETH","CBTA","PFS","BITY","DEFI","ORR","BITX","PD","BTRN","BTF","CBXY","MAXI","CBTO","CBTJ","HODL","CBOA","HCC","FBTC","BTCL","ARKB","BTCZ","BPI","DFII","CBXJ","SBIT","BAGY","QBF","BITB","BTCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660487132","title":"Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660487132","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660487132?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:00","pubTimestamp":1786964400,"startTime":"0","endTime":"0","summary":"The New Mechanistic Findings Support Can-Fite’s Ongoing Phase IIb Study Design Following Positive Phase IIa Results Ramat Gan, Israel, Aug.  17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/17/3345970/0/en/can-fite-namodenoson-enhances-the-anti-cancer-effect-of-chemotherapy-in-pancreatic-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAL","BK4006","HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659608123","title":"Tvardi: Strategic Pivot to Ulcerative Colitis and Upcoming HCC Readouts Support Unchanged $9 Price Target and Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2659608123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659608123?lang=en_us&edition=fundamental","pubTime":"2026-08-15 00:35","pubTimestamp":1786725333,"startTime":"0","endTime":"0","summary":"In a report released today, Sara Nik from H.C. Wainwright maintained a Buy rating on Tvardi Therapeutics, with a price target of $9.00. Sara Nik ha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tvardi-strategic-pivot-to-ulcerative-colitis-and-upcoming-hcc-readouts-support-unchanged-9-price-target-and-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tvardi-strategic-pivot-to-ulcerative-colitis-and-upcoming-hcc-readouts-support-unchanged-9-price-target-and-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.warriormetcoal.com","stockEarnings":[{"period":"1week","weight":-0.0732},{"period":"1month","weight":-0.1711},{"period":"3month","weight":0.0274},{"period":"6month","weight":-0.0863},{"period":"1year","weight":0.4067},{"period":"ytd","weight":0.0034}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":0.0102},{"period":"3month","weight":0.0544},{"period":"6month","weight":0.1776},{"period":"1year","weight":0.1654},{"period":"ytd","weight":0.1343}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Warrior Met Coal, Inc. produces and exports non-thermal metallurgical coal for the steel industry. It operates two underground mines located in Alabama. The company sells its metallurgical coal to a customer base of blast furnace steel producers located primarily in Europe, South America, and Asia. It also sells natural gas, which is extracted as a byproduct from coal production. Warrior Met Coal, Inc. was incorporated in 2015 and is headquartered in Brookwood, Alabama.","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.047428},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.016436},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.028693},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.010079},{"month":5,"riseRate":0.5,"avgChangeRate":0.016174},{"month":6,"riseRate":0.6,"avgChangeRate":-0.005518},{"month":7,"riseRate":0.7,"avgChangeRate":0.066127},{"month":8,"riseRate":0.5,"avgChangeRate":0.054739},{"month":9,"riseRate":0.6,"avgChangeRate":0.013077},{"month":10,"riseRate":0.555556,"avgChangeRate":0.03995},{"month":11,"riseRate":0.666667,"avgChangeRate":0.081356},{"month":12,"riseRate":0.777778,"avgChangeRate":0.058477}],"exchange":"NYSE","name":"Warrior Met Coal LLC","nameEN":"Warrior Met Coal LLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Warrior Met Coal LLC(HCC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Warrior Met Coal LLC(HCC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Warrior Met Coal LLC,HCC,Warrior Met Coal LLC股票,Warrior Met Coal LLC股票老虎,Warrior Met Coal LLC股票老虎国际,Warrior Met Coal LLC行情,Warrior Met Coal LLC股票行情,Warrior Met Coal LLC股价,Warrior Met Coal LLC股市,Warrior Met Coal LLC股票价格,Warrior Met Coal LLC股票交易,Warrior Met Coal LLC股票购买,Warrior Met Coal LLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Warrior Met Coal LLC(HCC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Warrior Met Coal LLC(HCC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}